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Abstract 
Genomic instability is one of the most common and critical characteristics of cancer cells. 
The combined effect of replication stress and DNA damage repair defects associated with 
various oncogenic events drives genomic instability and the disease progression. However, 
these DNA repair defects found in cancer cells can also provide unique therapeutic 
opportunities, which also form the basis of synthetic lethal targeting of solid tumours carrying 
BRCA mutations. While the idea of utilising synthetic lethality as a therapy strategy has been 
gaining momentum and progress in various solid tumours, its application in leukaemia still 
largely lags behind. In this article, we will review the recent advances in understanding the 
roles of DNA damage response in acute myeloid leukaemia (AML) and examine the potential 
therapeutic avenues of using PARP inhibitors in AML treatment. 
 
 
 
 
 
 
 
 
Keywords: AML, PARPi, synthetic lethality, BRCA, MLL leukemia, AML1-ETO, APL, 
PML-RARA, GSK3 inhibitors, HOXA9, MEIS1, MLL  
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Introduction 
Poly (ADP-ribose) polymerase (PARP) 1 and PARP2 belongs to the PARP protein 
superfamily that catalyses the polymerisation of ADP-ribose onto their target substrates using 
oxidized nicotinamide adenine dinucleotide (NAD+) as a co-substrate and releasing 
nicotinamide as a by-product. This posttranslational modification often regulates the 
conformation, stability and/or activity of the targeted proteins (1). Therefore, PARP1 is 
involved in a wide array of cellular processes ranging from DNA repair, gene transcription 
regulation to cell division. However, the best well characterised role of PARP1 is in single 
stranded break (SSB) repair in the DNA damage response (DDR) pathway (2). PARP1 
initiates this process by detecting and binding to the SSBs. Catalytic activity of PARP1 and 
PARP2 results in the PARsylation of PARP itself and a series of additional proteins involved 
in DDR. The rationale of using PARP inhibitors (PARPi) for cancer treatment has previously 
been suggested by studies from Ashworth's and Helleday's groups (3, 4).  This relies on their 
abilities to selectively kill BRCA1 or BRCA2 mutated breast or ovarian cancers with a 
defective repair of double stranded breaks (DSBs) by homologous recombination (HR) (5). 
Upon PARP inhibition, SSBs are continuously generated by endogenous oxidants, replication 
and oncogenic stresses, and can no longer be efficiently repaired by the base excision repair 
(BER) in which PARP1 and PARP2 play a key role. SSBs become DSBs as DNA 
polymerases travel along the replication forks. Normal cells are able to repair the DSBs by 
HR and survive. In contrast, HR-deficient BRCA1 or BRCA2 mutated cancer cells 
accumulate excessive DNA damages that are either unattended or repaired by the error-prone 
non-homologous end-joining (NHEJ) pathways leading to genomic instability and eventual 
cell death (1) (Figure 1).  In addition, it has also been reported that certain PARPi can trap 
PARP proteins onto DNA breaks which induces replication fork collapses (6). Thus, the 
concomitant inhibition of PARP activity in cancer cells with defective HR can induce 
synthetic lethal conditions providing a potential therapeutic strategy for a wide range of 
cancers including leukaemia. 
 
Targeting cancer genomes by PARPi-induced synthetic lethality 
 
With many PARPi currently being developed and tested in clinical trials, Lynparza 
(olaparib) is the only FDA approved drug for treatment of BRCA1 or BRAC2 mutated ovarian 
cancer, and is at the most advanced stage of targeted therapy for triple negative breast cancer 
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patients.  In addition to BRCA mutated cancers, the therapeutic potential of using PARPi also 
extends to cancers bearing mutations affecting other key components of HR including ATM, 
ATR, CHK1, RAD51 along with their homologues and the FANC family proteins. PARPi 
was reported to have activity in cells defective in several of these proteins (7). While 
mutations affecting classical HR genes can only been found in small subtypes of cancers (8), 
the continuous exploration of novel player in DNA damage responses reveals an 
unexpectedly critical function mediated by PTEN, one of the most commonly mutated 
tumour suppressors in human cancer. While cytoplasmic PTEN antagonizes PI3K signalling 
pathway for tumour suppression, nuclear PTEN regulated by SUMOylation and ATM 
phosphorylation mediates DNA repair upon exposure to IR or DNA damaging agents (9).  
Cells lacking nuclear PTEN were hypersensitive to DNA damage, and were susceptible to 
killing by a combination of genotoxic stress and PI3K inhibitors. While these findings may 
extend the potential application of synthetic lethality in a wider range of cancer subtypes, 
PTEN and HR gene mutations can only be found in a very small fraction of AMLs (9), which 
is frequently driven by mutated transcription factors and epigenetic regulators (10).  Given 
the critical functions of transcriptional deregulation in acute leukaemogenesis, we and others 
have speculated the potential application of synthetic lethality approach to target the 
compromised DDR, resulted from aberrant transcriptional networks, in the leukaemic cells 
(8).   
 
Targeting aberrant transcriptional programmes in leukaemia by PARPi-induced 
synthetic lethality 
 
There is compelling evidence that chimeric transcription factors found in AML result 
in repression of one or several DDR pathways leading to genomic instability.  AML1-ETO, 
which accounts for about 10% of adult AML, is found to repress a variety of genes involved 
in DDR in particular proteins involved in BER (OGG1, FEN1, MPG, POLD2) and HR 
pathway (ATM, RAD51, BRCA1) (11, 12) . These defects in DDR are accompanied with high 
level of DNA damage characterised by the ƴH2AX and an increase in mutation frequencies 
(11-15). Similarly, PML-RARα fusion in acute promyelocytic leukaemia (APL) represses a 
large array of genes in DDR such as in the BER pathway (FEN1, LIG3, MPG OGG1), and 
HR (RPA1, BRCA1, RAD51) (11, 16) . Studies from Zhong et al. also suggest that PML is 
essential in multiple steps of HR (17). Loss of PML impairs the recruitment of MRE11, 
RPA1, BRCA1, and RAD51 to DNA damage foci, whereas PML-RARα directly disrupts the 
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localisation and activity of BLM and PML. RAD51 protein levels were also downregulated 
upon PML knockdown in another study, indicating that PML might be required for RAD51 
stability (18). Strikingly, PML counteracts HAUSP function in regulating PTEN 
ubiquitinylation and nuclear localization via the adaptor protein DAXX that inhibits HAUSP-
mediated deubiquitinylation of PTEN (19).  While PML promotes nuclear location of PTEN, 
expression of PML-RARα fusion can suppress PML function and PTEN nuclear localization.   
Using mouse primary transformed cells and human leukaemic cells, we along with 
others further demonstrated specific suppression of HR transcriptional programmes and 
accumulation of excessive DNA damage in AML1-ETO or PML-RARα leukaemic cells, 
which were uniquely sensitive to PARPi treatment both in vitro and in vivo (14).  
Consistently, Kasumi-1 cells expressing AML1-ETO were less sensitive to PARPi upon 
AML1-ETO knockdown (20).  Moreover, PARPi as a mono-therapy exhibited strong 
oncogenic suppression property of ATRA-resistant APL cells both in vitro and in vivo in a 
xenograft model, extending the potential application of PARPi for treatment resistant APL 
(14).  On the other hand, abberant suppression of other DDR mediators in leukaemia cells 
may also be permissive for PARPi-induced leathality. While PTEN mutations are not 
common in AML, reduced expression of PTEN has been implicated in BCR-ABL induced 
chronic myeloid leukiemia (CML) (21) and PTEN-deficient mice developed 
myeloproliferative disorders and acute leukaemias (22, 23). PTEN was found to be important 
for the expression of RAD51 (24). It was shown that PTEN-defficient cells are extremely 
sensitive to PARPi providing the rationale for ongoing studies of using PARPi in PTEN 
defficient tumours (25, 26). On the other hand, Faroani et al. reported undetectable BRAC1 
and BRAC2 protein expression and reduced expression mRNA expression in primary AML 
patient samples, suggesting BRCAness phenotype due to transcriptional and/or translational 
repression of BRCA1 and BRCA2 (27).  Moreover, a reduced BRCA1 expression due to 
promoter hypermethylation was also reported in therapy-related AML cells that might be 
sensitive to PARPi (28).  Therefore, these findings provide a strong rationale to apply PARPi 
for leukaemia treatment.  
 
Combination therapy with PARPi for refractory AML  
In addition to utilising PARPi as a monotherapy in specific AML subtype, there are 
potential scopes of combining PARPi with other inhibitors for AML.  As compared to 
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AML1-ETO or PML-RARα leukaemic cells, leukaemia driven by MLL fusion proteins that 
activate expression of HR genes in part via HOXA9 are resistant to PARPi treatment (14). We 
showed that modulation of HOXA9 transcription activity could synergize with PARPi in 
targeting MLL rearranged leukaemia. Suppression of Hoxa9 by genetic approach or 
inhibiting one of its co-regulators, glycogen synthase kinase 3 (GSK3) could sensitise MLL 
rearranged leukaemic cells to PARPi treatment. Combination of GSK3 inhibitor, Li2CO3, and 
PARPi could robustly suppress MLL-AF9 leukaemia and significantly extended the disease 
latency in both primary syngeneic mouse model and primary human MLL leukaemia 
xenotransplant model. Therefore simultaneously targeting of PARP and the GSK3–HOXA9 
axis can be a potential therapeutic approach to MLL rearranged leukaemia, which often 
confers a poor prognosis (14).  Similar principle can also be applied to BRCA proficient cells. 
Cyclin D1 (CDK1) mediated phosphorylation of BRCA1 is essential for efficient DNA repair 
foci formation (29). Application of CDK1 inhibitor supressed HR and induced PARPi 
sensitivity in non–small-cell-lung cancer both in vitro and in vivo (29).    
On the other hand, there are also indications for the potential use of PARPi as a 
chemotherapy sensitizer in leukaemia, although the mechanisms are not well defined.  
Falzacappa et al. reported that the combination of PARPi, Rucaparib, and conventional 
chemotherapy agent, fluorouracil, was effective in killing AML cells in vitro and in vivo (30).  
Fluorouracil was shown to induced DNA damage and together with the repression of the 
DDR by PARPi, the combination resulted in a significant increase in DNA damage leading to 
cell cycle arrest and death (30). Similar observation was found using AML cell lines exposed 
to histone deacetylase (HDAC) inhibitors and PARPi (31). HDACs catalyse the removal of 
acetyl groups from histone and other non-histone proteins altering gene expression and 
protein stability/function (32). HDAC inhibitors were reported to sensitise cancer cells to 
DNA damaging therapies such as irradiation and various chemotherapeutics by altering 
chromatin structure and down-regulating HR genes (33, 34). Thus, it is perhaps unsurprising 
that HDACs was found to synergise with PARPi in AML cell lines in vitro leading to 
significant increase in ƴH2AX upon combined treatments (31, 35).  Simultaneous targeting 
cancers cells with temozolomide and PARPi have been shown successfully in vitro and in 
vivo in a number of cancers including AML (36-38). Temolozolomide has limited clinical 
utility other than for neurological malignancies and melanoma. It alkylates or methylates 
DNA, which most often occurs at the N-7 or O-6 positions of guanine residues. The excision 
of these N-methylpurines generates SSBs. PARP inactivation potentiates the effects of 
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temolozomide by inhibiting repair of these SSBs via BER. Under the same paradigm, DNA 
methyltransferases (DNMT) inhibitors (DNMTi) including 5-azacytidine and 5-aza-2'-
deoxycytidine, have been reported to synergise with PARPi, olaparib (39). While the 
therapeutic mechanism of DNMT inhibitors in myelodysplastic syndrome (MDS) and AML 
is thought to be in part mediated by their DNA demethylation activity resulting in 
reactivation of silenced tumour suppressor genes (40) and induction of dsRNAs derived from 
endogenous retroviral elements that triggers interferon-dependent immune checkpoint (41, 
42), Orta et al. showed that BER was crucial for recognizing and repairing DNA lesions 
induced by DNMTi. BER deficient cells were sensitive to 5-azacytidine and displayed an 
increased amount of DNA single and double-strand breaks. PARP inhibition prevented 
recruitment of XRCC1 to the damage sites and therefore compromised BER. Combining 5-
azacytidine and olaparib was found to cause synthetic lethality in a number of AML cell lines 
suggesting that PARP inhibitors can be used in combination with 5-azacytidine to improve 
treatment of MDS and AML patients.  
 
Conclusions 
PARPi alone or in combination with other treatments clearly exhibit various efficacies 
in targeting different subsets of leukaemia. Although the majority of the trials focus on the 
use of PARPi in solids tumours with BRCA mutations, several clinical trials are currently 
underway investigating the efficacy of PARPi in leukaemia (Table 1), where BRCA 
mutations are rare, which may in part explain only a limited number of PARPi clinical trials 
in AML. The major challenge of using PARPi in AML may come down to identifying 
reliable biomarkers to predict the treatment responses, which are largely determined by the 
driver mutations in leukaemia cells. By dissecting the molecular and transcriptional functions 
of these driver mutations in AML, we and others have revealed that PARPi can be 
particularly effective for treatment of leukaemia induced by certain oncogenic transcription 
factors (such as AML1-ETO and PML-RARα), which are classically intractable targets. 
PARPi can also be used in combination with GSK3i, chemotherapy or DNMTi to target MLL 
rearranged or other leukaemias.  However, given the heterogeneity of the disease with 
patients carrying various additional cooperative mutations, it is likely that degree of treatment 
response to PARPi will vary between patients and within the tumour itself.  In addition, some 
mutations may have opposing impacts on DDR, which are likely context dependent.  For 
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example, FLT3-ITD, frequently found in AML has been reported to both induce DNA 
damages by inducing production of radical oxygen species (8) and promote HR via increased 
expression of HR genes (43, 44).  It is critical to determine empirically the mechanisms and 
impacts of these cooperative mutations on PARPi sensitivity in AML patients. On the other 
hand, it is clear that PARPs have other diverse molecular functions beyond DDR that may 
also be critical for cancer survival and the observed synthetic lethality.  A better 
understanding of the biological function of PARPs, cancer-driver mutations and their 
potential interactions is critical for designing better and effective cancer therapeutic strategies. 
 
Acknowledgements 
This work is supported by Bloodwise, Cancer Research UK and Kay Kendall Leukaemia 
Fund. 
 
Finacial interetest 
 
The authors declare no competing financial interest. 
 
Reference 
1. M. Rouleau, A. Patel, M. J. Hendzel, S. H. Kaufmann, G. G. Poirier, PARP inhibition: 
PARP1 and beyond. Nat Rev Cancer 10, 293-301 (2010). 
2. C. J. Lord, A. Ashworth, The DNA damage response and cancer therapy. Nature 481, 
287-294 (2012). 
3. H. E. Bryant et al., Specific killing of BRCA2-deficient tumours with inhibitors of 
poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005). 
4. H. Farmer et al., Targeting the DNA repair defect in BRCA mutant cells as a 
therapeutic strategy. Nature 434, 917-921 (2005). 
5. S. B. De Lorenzo, A. G. Patel, R. M. Hurley, S. H. Kaufmann, The Elephant and the 
Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination 
Deficient Tumor Cells. Front Oncol 3, 228 (2013). 
6. T. Helleday, The underlying mechanism for the PARP and BRCA synthetic lethality: 
clearing up the misunderstandings. Mol Oncol 5, 387-393 (2011). 
7. N. McCabe et al., Deficiency in the repair of DNA damage by homologous 
recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 
66, 8109-8115 (2006). 
8. M. T. Esposito, C. W. So, DNA damage accumulation and repair defects in acute 
myeloid leukemia: implications for pathogenesis, disease progression, and 
chemotherapy resistance. Chromosoma 123, 545-561 (2014). 
9. C. Bassi et al., Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. 
Science 341, 395-399 (2013). 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10. B. B. Zeisig, A. G. Kulasekararaj, G. J. Mufti, C. W. So, SnapShot: Acute myeloid 
leukemia. Cancer Cell 22, 698-698 e691 (2012). 
11. M. Alcalay et al., Acute myeloid leukemia fusion proteins deregulate genes involved 
in stem cell maintenance and DNA repair. J Clin Invest 112, 1751-1761 (2003). 
12. O. Krejci et al., p53 signaling in response to increased DNA damage sensitizes 
AML1-ETO cells to stress-induced death. Blood 111, 2190-2199 (2008). 
13. V. J. Forster et al., The leukemia-associated RUNX1/ETO oncoprotein confers a 
mutator phenotype. Leukemia 30, 250-253 (2016). 
14. M. T. Esposito et al., Synthetic lethal targeting of oncogenic transcription factors in 
acute leukemia by PARP inhibitors. Nat Med 21, 1481-1490 (2015). 
15. V. J. Forster et al., The leukemia-associated RUNX1/ETO oncoprotein confers a 
mutator phenotype. Leukemia 30, 251-254 (2016). 
16. I. Casorelli et al., Identification of a molecular signature for leukemic promyelocytes 
and their normal counterparts: Focus on DNA repair genes. Leukemia 20, 1978-1988 
(2006). 
17. S. Zhong et al., A role for PML and the nuclear body in genomic stability. Oncogene 
18, 7941-7947 (1999). 
18. S. Boichuk, L. Hu, K. Makielski, P. P. Pandolfi, O. V. Gjoerup, Functional 
connection between Rad51 and PML in homology-directed repair. PLoS One 6, 
e25814 (2011). 
19. M. S. Song et al., The deubiquitinylation and localization of PTEN are regulated by a 
HAUSP-PML network. Nature 455, 813-817 (2008). 
20. C. Q. Wang et al., Disruption of Runx1 and Runx3 leads to bone marrow failure and 
leukemia predisposition due to transcriptional and DNA repair defects. Cell Rep 8, 
767-782 (2014). 
21. C. Peng et al., PTEN is a tumor suppressor in CML stem cells and BCR-ABL-
induced leukemias in mice. Blood 115, 626-635 (2010). 
22. O. H. Yilmaz et al., Pten dependence distinguishes haematopoietic stem cells from 
leukaemia-initiating cells. Nature 441, 475-482 (2006). 
23. J. Zhang et al., PTEN maintains haematopoietic stem cells and acts in lineage choice 
and leukaemia prevention. Nature 441, 518-522 (2006). 
24. W. H. Shen et al., Essential role for nuclear PTEN in maintaining chromosomal 
integrity. Cell 128, 157-170 (2007). 
25. K. J. Dedes et al., PTEN deficiency in endometrioid endometrial adenocarcinomas 
predicts sensitivity to PARP inhibitors. Sci Transl Med 2, 53ra75 (2010). 
26. A. M. Mendes-Pereira et al., Synthetic lethal targeting of PTEN mutant cells with 
PARP inhibitors. EMBO Mol Med 1, 315-322 (2009). 
27. I. Faraoni et al., BRCA1, PARP1 and gammaH2AX in acute myeloid leukemia: Role 
as biomarkers of response to the PARP inhibitor olaparib. Biochim Biophys Acta 1852, 
462-472 (2015). 
28. P. Moskwa et al., miR-182-mediated downregulation of BRCA1 impacts DNA repair 
and sensitivity to PARP inhibitors. Mol Cell 41, 210-220 (2011). 
29. N. Johnson et al., Compromised CDK1 activity sensitizes BRCA-proficient cancers to 
PARP inhibition. Nat Med 17, 875-882 (2011). 
30. M. V. Falzacappa et al., The Combination of the PARP Inhibitor Rucaparib and 5FU 
Is an Effective Strategy for Treating Acute Leukemias. Mol Cancer Ther 14, 889-898 
(2015). 
31. T. J. Gaymes et al., Histone deacetylase inhibitors (HDI) cause DNA damage in 
leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis? Mol 
Cancer Res 4, 563-573 (2006). 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
32. K. T. Thurn, S. Thomas, A. Moore, P. N. Munster, Rational therapeutic combinations 
with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 7, 263-
283 (2011). 
33. S. K. Kachhap et al., Downregulation of homologous recombination DNA repair 
genes by HDAC inhibition in prostate cancer is mediated through the E2F1 
transcription factor. PLoS One 5, e11208 (2010). 
34. S. Adimoolam et al., HDAC inhibitor PCI-24781 decreases RAD51 expression and 
inhibits homologous recombination. Proc Natl Acad Sci U S A 104, 19482-19487 
(2007). 
35. T. J. Gaymes et al., Inhibitors of poly ADP-ribose polymerase (PARP) induce 
apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and 
myelodysplastic syndromes. Haematologica 94, 638-646 (2009). 
36. T. J. Gaymes et al., Microsatellite instability induced mutations in DNA repair genes 
CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors 
in myeloid malignancies. Haematologica 98, 1397-1406 (2013). 
37. M. Javle, N. J. Curtin, The potential for poly (ADP-ribose) polymerase inhibitors in 
cancer therapy. Ther Adv Med Oncol 3, 257-267 (2011). 
38. T. M. Horton et al., Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the 
cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair 
status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther 8, 
2232-2242 (2009). 
39. M. L. Orta et al., The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-
2'-deoxycytidine lesions. Nucleic Acids Res 42, 9108-9120 (2014). 
40. J. P. Issa et al., Phase 1 study of low-dose prolonged exposure schedules of the 
hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic 
malignancies. Blood 103, 1635-1640 (2004). 
41. D. Roulois et al., DNA-Demethylating Agents Target Colorectal Cancer Cells by 
Inducing Viral Mimicry by Endogenous Transcripts. Cell 162, 961-973 (2015). 
42. K. B. Chiappinelli et al., Inhibiting DNA Methylation Causes an Interferon Response 
in Cancer via dsRNA Including Endogenous Retroviruses. Cell 162, 974-986 (2015). 
43. K. Bagrintseva et al., FLT3-ITD-TKD dual mutants associated with AML confer 
resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). 
Blood 105, 3679-3685 (2005). 
44. C. H. Seedhouse et al., DNA repair contributes to the drug-resistant phenotype of 
primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is 
reversed by the FLT3 inhibitor PKC412. Leukemia 20, 2130-2136 (2006). 
 
Figure 1: Schematics of applying synthetic lethality in AML 
Reactive oxygen species (ROS) or replication stress causes DNA single-strand breaks (SSBs) 
that are normally repaired by base excision repair (BER). PARP inhibitors block BER 
pathway, leading SSBs to become double-strand breaks (DSBs) as DNA polymerase moves 
along the replication forks. In normal cells, homologous recombination can repair these 
breaks. However, cancer cells with mutations or transcriptional repression of  HR genes (i.e. 
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BRCA1 or BRCA2) are unable to efficiently repair these damages leading to genomic 
instability and eventual cell death. 
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Highlights: 
• Synthetic lethal targeting of cancer genomes by PARP inhibitors (PARPi) 
• Targeting aberrant transcription programmes by PARPi-induced synthetic lethality 
• Potential use of PARPi as monotherapy in AML 
• PARPi in combination with other agents in AML 
